Current advances and trends in the treatment of depression
- PMID: 7940983
- DOI: 10.1016/0165-6147(94)90315-8
Current advances and trends in the treatment of depression
Abstract
The pathophysiology of major affective illness is poorly understood. However, several lines of preclinical and clinical evidence indicate that an enhancement of 5-HT-mediated neurotransmission might underlie the therapeutic effect of most antidepressant treatments. This net effect would, however, be obtained via different mechanisms. A better understanding of the neurobiological basis for the delayed onset of action of antidepressant treatments has led to the elaboration of strategies that could accelerate the antidepressant response. These strategies are discussed in this article by Pierre Blier and Claude de Montigny.
Comment in
-
Risks in combination therapy of antidepressant drugs.Trends Pharmacol Sci. 1995 Jan;16(1):17. doi: 10.1016/s0165-6147(00)88966-x. Trends Pharmacol Sci. 1995. PMID: 7732598 No abstract available.
Similar articles
-
Recent developments in the acute somatic treatment of major depression.J Clin Psychiatry. 1992 Mar;53 Suppl:20-5. J Clin Psychiatry. 1992. PMID: 1347770 Review.
-
Early onset of therapeutic action in depression and greater efficacy of antidepressant treatments: are they related?Int Clin Psychopharmacol. 1997 Jul;12 Suppl 3:S21-8. doi: 10.1097/00004850-199707003-00004. Int Clin Psychopharmacol. 1997. PMID: 9347389 Review.
-
Modifications of the serotonin system by antidepressant treatments: implications for the therapeutic response in major depression.J Clin Psychopharmacol. 1987 Dec;7(6 Suppl):24S-35S. J Clin Psychopharmacol. 1987. PMID: 3323264 Review.
-
ECT versus tricyclic antidepressants in depression: a review of the evidence.J Clin Psychiatry. 1988 Jan;49(1):3-7. J Clin Psychiatry. 1988. PMID: 3275634 Review.
-
Serotonin and drug-induced therapeutic responses in major depression, obsessive-compulsive and panic disorders.Neuropsychopharmacology. 1999 Aug;21(2 Suppl):91S-98S. doi: 10.1016/S0893-133X(99)00036-6. Neuropsychopharmacology. 1999. PMID: 10432494 Review.
Cited by
-
Participation of the Serotonergic System and Brain-Derived Neurotrophic Factor in the Antidepressant-like Effect of Flavonoids.Int J Mol Sci. 2022 Sep 17;23(18):10896. doi: 10.3390/ijms231810896. Int J Mol Sci. 2022. PMID: 36142808 Free PMC article. Review.
-
Impact of paroxetine on sleep problems in 426 cancer patients receiving chemotherapy: a trial from the University of Rochester Cancer Center Community Clinical Oncology Program.Sleep Med. 2012 Oct;13(9):1184-90. doi: 10.1016/j.sleep.2012.06.001. Epub 2012 Aug 2. Sleep Med. 2012. PMID: 22858235 Free PMC article. Clinical Trial.
-
Deletion of GIRK2 Subunit of GIRK Channels Alters the 5-HT1A Receptor-Mediated Signaling and Results in a Depression-Resistant Behavior.Int J Neuropsychopharmacol. 2015 May 8;18(11):pyv051. doi: 10.1093/ijnp/pyv051. Int J Neuropsychopharmacol. 2015. PMID: 25956878 Free PMC article.
-
Neuroadaptations to chronic exposure to drugs of abuse: relevance to depressive symptomatology seen across psychiatric diagnostic categories.Neurotox Res. 2002 Jun;4(4):297-313. doi: 10.1080/10298420290023963. Neurotox Res. 2002. PMID: 12829420
-
Effects of acute treatment with paroxetine, citalopram and venlafaxine in vivo on noradrenaline and serotonin outflow: a microdialysis study in Swiss mice.Br J Pharmacol. 2003 Nov;140(6):1128-36. doi: 10.1038/sj.bjp.0705538. Epub 2003 Oct 6. Br J Pharmacol. 2003. PMID: 14530210 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical